{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T22:57:45Z","timestamp":1694473065304},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100008867","name":"Department of Education of Zhejiang Province","doi-asserted-by":"crossref","award":["20100264"],"award-info":[{"award-number":["20100264"]}],"id":[{"id":"10.13039\/501100008867","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.clinthera.2012.04.027","type":"journal-article","created":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T12:03:46Z","timestamp":1337169826000},"page":"1432-1439","source":"Crossref","is-referenced-by-count":6,"title":["Comparative Fasting Bioavailability of Dispersible and Conventional Tablets of Risperidone: A Single-Dose, Randomized-Sequence, Open-Label, Two-Period Crossover Study in Healthy Male Chinese Volunteers"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"chictr-trc-12001996","registry":"10.18810\/chictr"}],"author":[{"given":"Mingzhu","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhong","family":"Shen-Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingjiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junchun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.04.027_bib1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/0091270009347867","article-title":"Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety","volume":"50","author":"Xiang","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.04.027_bib2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1097\/FTD.0b013e3181aa4780","article-title":"Serum levels of risperidone and its metabolite 9-hydroxyrisperidone: correlation between drug concentration and clinical response","volume":"31","author":"Lostia","year":"2009","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2012.04.027_bib3","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1517\/14656566.1.7.1441","article-title":"Pharmacology and clinical experience with risperidone","volume":"7","author":"Love","year":"2000","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2012.04.027_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/0091270002239819","article-title":"Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia","volume":"43","author":"Yasui-Furukori","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.04.027_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/01.jcp.0000170686.27476.ab","article-title":"Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia","volume":"25","author":"Pajonk","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2012.04.027_bib6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0269881107077357","article-title":"Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia","volume":"21","author":"Wang","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.clinthera.2012.04.027_bib7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1592\/phco.28.10.1283","article-title":"Paliperidone extended-release for the treatment of schizophrenia","volume":"28","author":"Marino","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2012.04.027_bib8","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2165\/11204840-000000000-00000","article-title":"Paliperidone extended release: a review of its use in the management of schizophrenia","volume":"70","author":"Chwieduk","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2012.04.027_bib9","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S1461-5347(00)00247-9","article-title":"Recent technological advances in oral drug delivery a review","volume":"3","author":"Sastry","year":"2000","journal-title":"Pharm Sci Technol Today"},{"key":"10.1016\/j.clinthera.2012.04.027_bib10","series-title":"Controlled Drug Delivery-Fundamentals and Actions","first-page":"3","article-title":"Influence of drug properties and routes of drug administration on the design of sustained and controlled release systems","author":"Robinson","year":"1987"},{"key":"10.1016\/j.clinthera.2012.04.027_bib11","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0149-2918(03)80163-7","article-title":"Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers","volume":"25","author":"Van Schaick","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.04.027_bib12","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/BF02969428","article-title":"Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes","volume":"29","author":"Cho","year":"2006","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.clinthera.2012.04.027_bib13","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.clinthera.2010.11.006","article-title":"Relative bioavailability of two oral formulations of risperidone 2 mg: a single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers","volume":"32","author":"Rodrigues Belotto","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.04.027_bib18","first-page":"228","article-title":"Advance in search for pharmacokinetics of an atypical antipsychotic: risperidone [in Chinese]","volume":"20","author":"Zhou","year":"2004","journal-title":"Chin J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.04.027_bib19","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jchromb.2007.02.007","article-title":"Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC-MS\/MS","volume":"852","author":"Cabovska","year":"2007","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.clinthera.2012.04.027_bib21","first-page":"562","article-title":"Functions of the DAS software for pharmacological calculation","volume":"7","author":"Chen","year":"2002","journal-title":"Chin J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2012.04.027_bib24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2146\/ajhp070261","article-title":"Paliperidone for schizophrenia","volume":"65","author":"Dolder","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2012.04.027_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clinthera.2008.02.011","article-title":"Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia","volume":"32","author":"Fowler","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.04.027_bib26","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.clinthera.2010.09.013","article-title":"Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: a single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand","volume":"32","author":"Boonleang","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2012.04.027_bib27","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/PL00005334","article-title":"Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4","volume":"359","author":"Fang","year":"1999","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812002913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812002913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T03:31:28Z","timestamp":1588822288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812002913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S0149291812002913"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.04.027","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}